Green Leaf Pharmaceuticals: China's first compound liposome sylipeer innovation is about to enter clinical

On June 11, Green Leaf Pharmaceuticals announced that its clinical application for its self-developed anti-tumor innovation, the Iliticonfluene lipid injection (LY01616), has been accepted by the Drug Review Center of the State Drug Administration of China and is about to enter clinical trialsThis is the first declared clinical compound lipid drug, its preparation technology requirements are high, the process is difficult, showing that the green leaf pharmaceutical group in the field of compound lipid research and development and manufacturing to obtain a new breakthroughThe combined chemotherapy of Ilythikang combined fluorouretic is one of the first options for advanced colorectal cancerLY01616 is an innovative compound lipid containing both Iliticon and fluoroxeliac for the treatment of advanced colorectal cancer, which is not currently available worldwideCombined chemotherapy has become the standard solution for clinical treatment of tumors at home and abroadCompared with single-drug chemotherapy, combined chemotherapy can play a synergistic role by using different mechanisms of drug, thus reducing the occurrence of drug resistance and improving the effect of chemotherapyHowever, the efficacy of combined chemotherapy is closely related to the proportion of the drugs used, and a specific proportion of synergies helps to achieve the best outcomeFor traditional combined chemotherapy, due to the nature of the drug itself, different metabolic pathways in the body and other reasons, it is difficult to maintain the original synergy ratio after the combination drug into the body, affecting the actual efficacyLY01616 is precisely to solve this clinical problem, it will be combined drugs in a specific synergetic proportion package in the same lipid body, compared with the traditional combined chemotherapy methods have a number of advantages, including: 1) to carry drugs in a specific proportion, delivery of drugs to target tissue, better achieve the synergetic effect of combined chemotherapy;